Drug Trial Radar · NCT06959082
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 11, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- VSPharmTech Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Conditions
- Head and Neck Cancer Squamous Cell Carcinoma
Interventions
VS-101Drug
VS-101
CisplatinDrug
Cisplatin
RadiationRadiation
Radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: 6 months and 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut · Recruiting
NYU Langone Health
Manhattan, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.